Recombinant Lucilia Sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo

Biotechnology Progress

Volumn 27, Issue 3, 2011, Pages 870-874

  Britland, Stephen ^a   Smith, Annie ^a   Finter, Wayne ^b   Eagland, Donald ^b   Vowden, Kath ^c   Vowden, Peter ^c   Telford, Gary ^d   Brown, Alan ^d   Pritchard, David ^d  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b AGT Sciences Ltd   (United Kingdom)

^c BRADFORD ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Biotherapy; Chronic wound; Debridement; Lucilia sericata

Indexed keywords

ACTIVITY PROFILE; BIOTHERAPY; CHRONIC WOUNDS; DEBRIDEMENT; EX-VIVO; GEL ELECTROPHORESIS; LUCILIA SERICATA; MECHANISM OF ACTION; PH OPTIMA; SERINE PROTEASE; TOPICAL APPLICATION; WOUND MANAGEMENT;

ALKALINITY; AMINO ACIDS; ELECTROPHORESIS; ENZYME ACTIVITY; UREA;

HYDROGELS;

CHYMOTRYPSIN; LUCILIA CHYMOTRYPSIN B; RECOMBINANT PROTEIN;

ARTICLE; DEBRIDEMENT; FREEZE DRYING; HUMAN; HYDROGEL; METHODOLOGY; TOPICAL DRUG ADMINISTRATION; WOUND HEALING;

ADMINISTRATION, TOPICAL; CHYMOTRYPSIN; DEBRIDEMENT; FREEZE DRYING; HUMANS; HYDROGEL; RECOMBINANT PROTEINS; WOUND HEALING;

HEXAPODA; LUCILIA SERICATA;

EID: 79958296121     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.587     Document Type: Article

References (18)

1. Purwins S, Herberger K, Debus ES, Rustenbach SJ, Pelzer P, Rabe E, Schäfer E, Stadler R, Augustin M. Cost-of-illness of chronic leg ulcers in Germany. Int Wound J. 2010; 7: 97-102.
2. Williams D, Enoch S, Miller D, Price P, Harding KG. Effect of sharp debridement using curette on recalcitrant non-healing venous ulcers: a concurrently controlled, prospective cohort study. Wound Rep Regen. 2005; 13: 131-137.
3. Stephen-Haynes J, Thompson G. The different methods of wound debridement. Br J Comm Nurs. 2007; 12: S6-S16.
4. Chambers L, Woodrow S, Brown AP, Harris PD, Phillips D, Hall M, Church JCT, Pritchard DI. Degradation of extracellular matrix components by defined proteases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds. Br J Dermatol. 2003; 148: 14-23.
5. McEvoy GK. AHFS drug information. Am Soc Health Sys Pharm. 2007; 3555-3556.
6. Hooper SR, Kokes ELC. The effect of pH upon proteoloysis by papain. J Biol Chem. 1946; 167: 199-207.
7. Smith AG, Brown A, Telford G, Vowden K, Vowden P, Eagland D, Pritchard D, Britland ST. Lucilia Sericata (Greenbottle) larvae secrete a human neutrophil elastase resistant plasmin that stimulates PAR1-transduced cyr61 upregulation in human dermal microvascular endothelial cells. J Wound Care. 2011, submitted.
8. Telford G, Brown A, Seabra R, Horobin A, Rich A, English J, Pritchard D. Degradation of eschar from venous leg ulcers using a recombinant chymotrypsin from Lucilia sericata. Br J Dermatol. Doi: 10.1111/j.1365-2133.2010.09854.x.
9. Trengove NJ, Stacey MC, MacAuley S, Bennet N, Gibson J, Burslem F, Murphy G, Schultz G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Regen. 1999; 7; 442-452.
10. Greener B, Hughes AA, Bannister NP, Douglass J. Proteases and pH in chronic wounds. J Wound Care. 2005; 14: 59-61.
11. Konig M, Vanschneidt W, Augustin M, Kapp H. Enzymatic versus autolytic debridement of chronic leg ulcers: a prospective randomized trial. J Wound Care. 2005; 14; 320-323.
12. Thomas AML, Harding KG, Moore K. The structure and composition of wound eschar. J Wound Care. 1999; 8: 285-287.
13. Horobin AJ, Shakesheff KM, Woodrow S, Robinson C, Pritchard DI. Maggots and wound healing: the effects of Lucilia sericata larval secretions upon human dermal fibroblasts. Br J Dermatol. 2003; 148: 923-933.
14. Horobin AJ, Shakesheff KM, Pritchard DI. Maggots and wound healing: an investigation of the effects of secretions from Lucilia sericata Larvae upon the migration of human dermal fibroblasts over a fibronectin-coated surface. Wound Rep Regen. 2005; 13: 422-433.
15. Smith AG, Powis RA, Pritchard DI, Britland ST. Greenbottle (Lucilia Sericata) larval secretions delivered from a prototype hydrogel wound dressing accelerate the closure of model wounds. Biotechnol Progr. 2006; 22: 1690-1696.
16. Dumville JC, Worthy G, Martin Bland J, Cullum N, Dawson C, Iglesias C, Mitchell JL, Nelson EA, Soares MO, Torgerson DJ. Larval therapy for leg ulcers (VenUS II): randomised controlled trial. BMJ. 2009; 338: 773.
17. Sherman RA, Hall MJ, Thomas S. Medicinal maggots: an ancient remedy for some contemporary afflictions. Ann Rev Entemol. 2000; 45: 55-81.
18. Telford G, Brown AP, Kind A, English JSC, Pritchard DI. Maggot chymotrypsin I from Lucilia sericata is resistant to endogenous wound protease inhibitors. Br J Dermatol. 2011; 164: 192.